CINECA IRIS Institutional Research Information System

VANNI, Ester
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.931
EU - Europa 3.300
AS - Asia 1.643
SA - Sud America 98
OC - Oceania 49
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.078
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.778
CN - Cina 1.038
SE - Svezia 544
IT - Italia 506
IE - Irlanda 381
DE - Germania 371
FR - Francia 325
UA - Ucraina 215
FI - Finlandia 214
GB - Regno Unito 165
KR - Corea 160
AT - Austria 134
CA - Canada 125
IN - India 102
PL - Polonia 100
VN - Vietnam 86
JP - Giappone 81
RU - Federazione Russa 68
BR - Brasile 57
BE - Belgio 50
AU - Australia 44
GR - Grecia 40
ES - Italia 37
NL - Olanda 36
HK - Hong Kong 26
DK - Danimarca 24
MX - Messico 24
TW - Taiwan 22
RO - Romania 21
TR - Turchia 19
EG - Egitto 18
TH - Thailandia 18
PE - Perù 15
PT - Portogallo 15
ZA - Sudafrica 14
SG - Singapore 13
AR - Argentina 11
ID - Indonesia 10
CH - Svizzera 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
EU - Europa 7
IR - Iran 7
MY - Malesia 7
PK - Pakistan 7
RS - Serbia 7
CO - Colombia 6
IL - Israele 6
NO - Norvegia 6
PH - Filippine 6
SI - Slovenia 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
NZ - Nuova Zelanda 5
SA - Arabia Saudita 5
BG - Bulgaria 4
HU - Ungheria 4
SN - Senegal 4
BY - Bielorussia 3
DZ - Algeria 3
IQ - Iraq 3
LK - Sri Lanka 3
MU - Mauritius 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
EC - Ecuador 2
HR - Croazia 2
JO - Giordania 2
MQ - Martinica 2
CU - Cuba 1
CY - Cipro 1
ET - Etiopia 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MM - Myanmar 1
MV - Maldive 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
QA - Qatar 1
SC - Seychelles 1
UY - Uruguay 1
VA - Santa Sede (Città del Vaticano) 1
Totale 10.078
Salva come PNG Salva come JPEG
Città #
Chandler 616
Beijing 606
Dublin 378
Ann Arbor 322
Fairfield 302
Dearborn 270
Villeurbanne 228
Wilmington 205
Houston 199
Ashburn 189
Woodbridge 183
Jacksonville 151
Seattle 142
Torino 130
Vienna 130
Princeton 124
Medford 112
Cambridge 108
Nyköping 106
Redwood City 106
Warsaw 86
Pisa 82
Ottawa 77
Hangzhou 68
Boston 65
Dong Ket 54
New York 54
Fremont 47
Shanghai 47
Boardman 46
Brussels 38
Nanjing 30
Munich 29
Milan 27
Guangzhou 25
Norwalk 25
Athens 24
Hefei 24
Phoenix 17
Taipei 17
Tokyo 17
Rome 16
Wuhan 16
Falls Church 15
Hyderabad 15
Toronto 15
Lima 14
London 14
Duncan 13
Kunming 12
Pune 12
San Mateo 12
Seoul 12
Washington 12
Bologna 11
San Diego 11
Kempton Park 10
Madrid 10
Mountain View 10
Saint Petersburg 10
Shenyang 10
Silver Spring 10
Verona 10
Bangkok 9
Chengdu 9
Helsinki 9
Jinan 9
Stanford 9
Amsterdam 8
Changsha 8
Chongqing 8
Copenhagen 8
Düsseldorf 8
Los Angeles 8
West Jordan 8
Xian 8
Istanbul 7
Turin 7
Zhengzhou 7
Brooklyn 6
Federal 6
Gurgaon 6
Livorno 6
Redmond 6
Berlin 5
Bern 5
Bricherasio 5
Calgary 5
Central 5
Central District 5
Erlangen 5
Frankfurt am Main 5
Hanoi 5
Jakarta 5
Melbourne 5
New Delhi 5
Pittsburgh 5
Santiago 5
Singapore 5
Tianjin 5
Totale 6.016
Salva come PNG Salva come JPEG
Nome #
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease 583
From the metabolic syndrome to NAFLD or vice versa? 526
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 354
Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity 339
Integrated serum proteins and fatty acids analysis for putative biomarker discovery in inflammatory bowel disease 320
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 222
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 181
AISF position paper on liver disease and pregnancy. 180
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 178
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 166
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 152
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 143
A "systems medicine" approach to the study of non-alcoholic fatty liver disease. 138
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 137
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 134
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 134
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis 132
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 129
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 127
Increased epicardial fat and early signs of impaired diastolic and systolic left ventricular function in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic Fatty Liver Disease 126
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. 125
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 124
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 124
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 121
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 119
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with Non Alcoholic Fatty Liver Disease independent of diabetes, hypertension and dyslipidemia 118
Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease 113
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 113
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 112
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 111
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 110
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in Non Alcoholic Fatty Liver Disease 108
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease 105
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. 104
A comparative study between ultrasound evaluation, liver stiffness measurement and biopsy for staging of hepatic fibrosis in patients with chronic liver disease 104
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 104
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in Non Alcoholic Fatty Liver Disease 103
THE ROLE OF ANTI-IFI16 ANTIBODIES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD) 103
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 102
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 100
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 100
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 99
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepadtis (NASH). 98
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 98
Previous tuberculosis, hepatitis C virus and lichen planus. A report of 10 cases, a causal or casual link? 95
Serum free fatty acid composition is associated with different degrees of fibrosis. 94
PNPLA3 gene variants and insulin resistance in patients with genotype-1 chronic hepatitis C 93
Alteration in lipid metabolism after an oral fat load in patients with NAFLD. 93
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 91
Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. 90
Risk factors for arterial hypertension after liver transplantation 88
Clinical Patterns of hepatocellular carcinoma (HCC) in Non Alcoholic Fatty Liver Disease (NAFLD): a multicenter case-control study. 87
A web-based program for implementing lifestyle changing towards healthy diet and habitual physical activity in NAFLD 81
A new index of glutathione turnover (GSH_TI) and its association with severity of non-alcoholic fatty liver disease (NAFLD). 78
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity 77
Clinical Patterns of hepatocellular carcinoma (HCC) in Non Alcoholic Fatty Liver Disease (NAFLD): a multicenter case-control study. 77
Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with Nonalcoholic Fatty Liver Disease 76
Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic fatty Liver Disease 76
Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. 76
Genetic predictors of steatosis and fibrosis in nonalcoholic fatty liver disease (NAFLD) 75
Metabolic Syndrome after liver transplantation: have risk factors changed over time? 75
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 74
Practical out-patient management of autoimmune hepatitis 73
PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C 73
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study 70
Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance 68
Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in NASH. 66
Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage. 62
P178 Validation of the clinical utility of IFI16-based markers in IBD 60
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver 57
The Combination of Liver Stiffness Measurement and NAFLD Fibrosis Score Improves the Nonivasive Diagnostic Accuracy for Severe Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease 57
PNPLA3/adiponutrin genotype is strongly associated with metabolic syndrome components and liver damage in patients with Nonalcoholic Fatty Liver Disease 56
PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C 55
NAFLD and Hepatocellular Carcinoma: how big a problem is this really? 54
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes 53
Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: mith or reality? 48
The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance? 47
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and chronic hepatitis C. 46
Plasma adiponectin in non alcoholic fatty liver disease is related to hepatic insulin resistance and hepatic fat content 46
Plasma adiponectin in Non Alcoholic Fatty Liver Disease is related to hepatic insulin resistance and hepatic fat content 45
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms 43
Ductular reaction is an independent predictor of advanced fibrosis in NAFLD 43
Does nonalcoholic steatohepatitis (NASH) progress to cryptogenic cirrhosis (CC) and hepatocellular carcinoma (HCC) - A case-control study. 43
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis 42
Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? 42
The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with Non-alcoholic Fatty Liver Disease 42
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study 42
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepatitis (NASH). 41
Response to Dr. Sertoglu and Colleagues 41
Obesity and Liver Cancer 39
Insulin resistance is an independent defect in non-alcoholic steatohepatitis (NASH). 38
Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children 38
Early menopausal status is associated with the severity of liver fibrosis in italian patients with Non-alcoholic Fatty Liver Disease 37
Non-alcoholic steatohepatitis in patients cared in metabolic units 36
Different contribution of metabolic and viral steatosis to liver damage 36
Ghrelin in non-alcoholic fatty liver disease 34
Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic studies for the diagnosis of NAFLD 33
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity 32
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia; evidence from a case control study 31
Metformin (MET) vs. diet in Non Alcoholic Fatty Liver Disease (NAFLD): a randomized controlled clinical trial 31
Totale 10.315
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.946
article - articoli 0
book - libri 0
conference - conferenze 12.907
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.853
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019489 0 0 0 0 0 0 0 0 0 138 218 133
2019/20201.717 92 86 90 216 131 308 206 113 141 186 63 85
2020/20211.235 135 111 56 90 140 121 67 63 132 53 104 163
2021/20221.414 29 42 39 98 78 84 102 99 69 186 301 287
2022/20231.782 206 136 91 169 167 419 138 118 195 39 67 37
2023/2024650 109 134 49 67 44 138 25 58 4 22 0 0
Totale 10.479